Cogent Biosciences (COGT) Long-Term Investments (2023 - 2024)
Cogent Biosciences' (COGT) quarterly Long-Term Investments came in at $10.0 million in Q3 2024, down 70.32% year-on-year from $33.8 million in Q4 2023, and down 62.42% on a QoQ basis from $26.7 million in Q2 2024.
Cogent Biosciences (COGT) Long-Term Investments (2023 - 2024) Analysis & Trends
Cogent Biosciences (COGT) has 2 years of Long-Term Investments data on file, last reported at $10.0 million in Q3 2024.
- On a quarterly basis, Long-Term Investments fell 70.32% year-over-year to $10.0 million in Q3 2024; TTM through Sep 2024 was $10.0 million, a 70.32% decrease from a year earlier, with the FY2023 full-year figure at $7.5 million, changed N/A from the prior year.
- Long-Term Investments for Q3 2024 stood at $10.0 million, down from $26.7 million in the prior quarter.
- Over the last five years, Long-Term Investments for COGT reached as high as $33.8 million in Q3 2023 and fell as low as $7.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cogent Biosciences | 6.87 Bn | 6.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 10.03 Mn |
| Jun 30, 2024 | 26.69 Mn |
| Dec 31, 2023 | 7.46 Mn |
| Sep 30, 2023 | 33.79 Mn |
| Jun 30, 2023 | 21.51 Mn |